Ruxolitinib for the treatment of acute graft-versus-host disease: a retrospective analysis

URN to cite this document:: urn:nbn:de:bvb:355-epub-586029
DOI to cite this document:: 10.5283/epub.58602

Denk, Alexander

; Edinger, Matthias ; Weber, Daniela ; Holler, Ernst ; Fante, Matthias ; Meedt, Elisabeth ; Güneş, Sibel ; Poeck, Hendrik ; Mittermaier, Cornelia ; Herr, Wolfgang ; Wolff, Daniel

License: Creative Commons Attribution 4.0
PDF - Published Version
(1MB)

Date of publication of this fulltext: 04 Jul 2024 06:45

Alternative links to fulltext:DOI Publisher

This publication is part of the DEAL contract with Springer.

Details

Preview

Export bibliographical data

Abstract

Steroid-refractory acute graft-versus-host disease (aGvHD) is a serious complication after allogeneic hematopoietic stem cell transplantation, associated with significant mortality. Ruxolitinib was the first drug approved for aGvHD, based on results of the REACH2 trial; however, real-world data are limited. We retrospectively analyzed the safety and efficacy of ruxolitinib for treatment of aGvHD ...